A string of strategic deals including with Sanofi, Bayer and Nestle marked the last couple of months at Dr. Reddy's Laboratories Ltd., as the Indian firm plugs portfolio gaps and builds momentum along its journey to break into the top five position on the Indian market.
At the earnings call for the fourth quarter of fiscal 2024, Dr Reddy’s CEO, Erez Israeli, outlined the broad contours...








